Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice. Consult a qualified healthcare professional before making any decisions about medication.
Few regulatory stories in recent Australian healthcare history have moved as quickly, or generated as much public confusion, as the rise and fall of compounded semaglutide. Between 2022 and late 2024, tens of thousands of Australians accessed compounded versions of semaglutide through pharmacies and telehealth services. By October 2024, that pathway had been closed by government regulation. Understanding why it opened, why it closed, and what the landscape looks like in 2026 is essential for anyone navigating weight management options in Australia.
Semaglutide is the active ingredient in two TGA-registered medicines: Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management). Both are manufactured by Novo Nordisk under tightly controlled pharmaceutical conditions, and both have undergone rigorous clinical evaluation for safety, quality, and efficacy before receiving TGA approval.
Compounded semaglutide is a different product entirely. It is prepared by a licensed compounding pharmacist using bulk active pharmaceutical ingredient (API) sourced separately, not drawn from Novo Nordisk's supply chain. The resulting preparation may be presented as an injectable solution, often in multi-dose vials, and may be combined with other agents such as vitamin B12, NAD+, or even tirzepatide.
Because compounded medicines are not TGA-registered products, they do not carry the same regulatory evaluation. The TGA has stated clearly that compounded semaglutide-like products "have not been evaluated for safety, quality or efficacy" and are not equivalent to Ozempic or Wegovy.
To understand the compounding episode, the shortage context is essential. Beginning in 2022 and intensifying sharply through 2023, global demand for semaglutide (driven by off-label weight loss prescribing, viral social media coverage, and celebrity endorsements) overwhelmed Novo Nordisk's manufacturing capacity worldwide.
Australia, as a relatively small market, bore a disproportionate share of the consequences. The TGA declared Ozempic an Actual Shortage at multiple points during 2023. Pharmacies received partial stock allocations. Patients with type 2 diabetes who had been stable on the medication for years faced forced interruptions. At the same time, demand from patients seeking Ozempic off-label for weight loss, a legal but off-label use, continued to grow.
In this environment, compounding pharmacies offered what appeared to be a practical solution. Under the Therapeutic Goods Regulations 1990, pharmacists had historically been permitted to compound medicines that were either unavailable or not commercially viable. With Ozempic in declared shortage, many compounders argued, and some regulators initially accepted, that the shortage condition justified compounding semaglutide-like products.
The result was rapid growth. Estimates cited in Australian parliamentary and health-policy discussions suggested that at the peak, approximately 20,000 Australians were injecting compounded replica weight loss products sourced from compounding pharmacies.
For more background on the Ozempic shortage and its resolution, see the detailed guide to Ozempic in Australia 2026.
By mid-2024, the TGA and the Australian Government had concluded that the public health risk from compounded GLP-1 products outweighed any access benefit. The regulatory response was swift.
In mid-2024, the TGA initiated a targeted consultation on removing GLP-1 receptor agonist analogues from the pharmacist extemporaneous compounding exemption under Schedule 5, Item 6 of the Therapeutic Goods Regulations 1990. Stakeholder submissions were accepted from healthcare professionals, pharmacy bodies, patient groups, and industry.
The TGA reported unanimous agreement among respondents that current regulatory arrangements needed strengthening, with broad support for a national approach to restricting GLP-1 RA compounding. This consensus was unusually strong for a regulatory consultation of this type.
From 1 October 2024, amendments to the Therapeutic Goods Regulations 1990 took effect. Under these amendments:
The Australian Government's official position, articulated by the then Health Minister, was that the ban was necessary to protect Australians from "unsafe compounding of replica weight loss products."
These changes are documented in the TGA's media release on GLP-1 RA pharmacy compounding changes and in the Department of Health's ministerial statement.
Following the ban, the TGA moved on compliance. In April 2025, the TGA accepted a court-enforceable undertaking from Your Solution Compounding Pharmacy Pty Ltd regarding advertising of prescription-only compounded medicines for weight loss, indicating that enforcement action against non-compliant pharmacies was ongoing.
The TGA's decision was not purely procedural. Several concrete safety concerns had accumulated in the period before the ban.
Compounding pharmacies operate under different conditions than pharmaceutical manufacturers. GLP-1 RA injectables are sterile, high-risk medicines, the same class as insulin. Replicating the precision required for consistent concentration, sterility, and stability in a compounding environment is technically demanding. The TGA noted:
Some compounded products were found to contain semaglutide combined with other active agents not present in the registered product, vitamin B12, NAD+, and in some cases tirzepatide. These combinations had no clinical evaluation data supporting their safety or rationale.
A recent pharmacovigilance study analysed compounded GLP-1 receptor agonist safety using the FDA Adverse Event Reporting System, the largest available database of post-market adverse event reports. The study (PMID 40285721) found that compounded GLP-1 RA formulations showed higher reporting odds ratios for abdominal pain, nausea, diarrhoea, cholecystitis, and suicidality compared to non-compounded formulations, and that preparation and prescribing errors were disproportionately represented in the compounded cohort.
While this data is drawn from the US regulatory system, the mechanism is identical: the risks of compounded GLP-1 products are not specific to geography.
The TGA's own compounding safety information for semaglutide-like products documents the Australian adverse event signals that informed the regulatory response.
As of 2026, the position is unambiguous.
Compounded semaglutide cannot legally be prescribed or dispensed in Australia. The October 2024 amendments closed the pathway definitively. There is no shortage exemption, no telehealth workaround, and no state-level variation, the ban operates under Commonwealth regulations and applies nationally.
Patients who were receiving compounded semaglutide prior to October 2024 are expected to have transitioned to either TGA-registered products or other treatment pathways. Any compounding pharmacy continuing to produce GLP-1 RA products after that date is operating outside the law and subject to TGA enforcement action.
Telehealth services that were previously prescribing compounded semaglutide are no longer able to do so lawfully. Some services have pivoted to prescribing TGA-registered alternatives, Ozempic for those with a type 2 diabetes indication, or Wegovy for eligible patients under the chronic weight management indication.
It is also worth noting: the ban applies specifically to compounding. Prescribing TGA-registered semaglutide off-label (for example, prescribing Ozempic for weight loss in a patient without diabetes) remains a lawful exercise of prescriber discretion and is not affected by the compounding regulations.
If you accessed compounded semaglutide prior to October 2024 and are wondering what this means for you:
The most direct pathway is to discuss with your GP or prescribing doctor whether you are eligible for a TGA-registered semaglutide product. Ozempic is available via PBS for type 2 diabetes and via private prescription off-label for weight management. Wegovy is TGA-registered for chronic weight management. See the Wegovy PBS listing guide for current PBS access information.
The TGA has recommended that patients not use compounded GLP-1 products prepared after 1 October 2024 and to consult their healthcare provider if uncertain about the provenance of any product in their possession. For any products obtained before the ban, the same caution applies, quality and stability cannot be verified.
Some telehealth services that were operating compounded semaglutide prescribing businesses have either closed, pivoted to registered-product prescribing, or are under TGA scrutiny. If your previous provider is no longer accessible, any GP can provide a new assessment and prescription for registered alternatives.
The closure of the compounding pathway does not mean Australians are without options. The registered product landscape has improved considerably.
TGA-approved for type 2 diabetes. Available via PBS for eligible patients (~$42.50 general, ~$7.70 concession). Available via private prescription off-label for weight management. Supply has substantially recovered from the 2023 shortage.
TGA-approved specifically for chronic weight management in adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities. Not yet PBS-listed: the PBAC recommended it for listing at its November 2025 meeting, for adults with established cardiovascular disease and obesity, with the listing not yet in effect. Private prescription costs apply in the interim.
TGA-approved for type 2 diabetes. Shows superior weight loss outcomes to semaglutide in head-to-head SURMOUNT trial data. PBS listing for the weight management indication is under review.
For patients who cannot access or afford registered GLP-1 therapy, evidence-based lifestyle and dietary interventions that support endogenous GLP-1 activity (including high-fibre diets, resistance training, and specific probiotic strains) offer a foundation for metabolic management. These do not replicate the clinical efficacy of pharmacological GLP-1 therapy but are a meaningful complement. See the complete guide to managing GLP-1 side effects and optimising outcomes for practical protocols.
The regulatory closure of the compounding pathway does not diminish the scientific interest in semaglutide as a molecule. GLP-1 receptor agonism remains one of the most actively researched mechanisms in metabolic medicine, with ongoing investigation into effects on cardiovascular outcomes, neuroinflammation, addiction pathways, and neurodegenerative disease.
Preclinical and translational research programmes require access to validated, characterised semaglutide compounds for receptor binding studies, mechanism-of-action work, and pharmacodynamic modelling. For researchers and institutions working in this area, research-grade semaglutide peptides for laboratory use are available through specialised suppliers, distinct from the clinical and therapeutic supply chain.
The regulatory story of compounded semaglutide in Australia is ultimately a case study in what happens when genuine unmet demand meets an inadequate supply of a registered medicine, and how quickly safety risks can scale when pharmaceutical-grade manufacturing standards are bypassed. With supply now stabilised and the registered product landscape broadening, the access rationale for compounded alternatives has dissolved alongside its legal basis.
Sources referenced in this article:
Emerging research on GLP-1 receptor agonists and alcohol cravings: 2025 RCT data, the reward-pathway mechanism, and what it means for semaglutide users.
Comparing bariatric surgery and GLP-1 medications on efficacy, durability, cost, and risk in Australia today, plus a practical decision framework for 2026.
The SELECT trial showed semaglutide cut MACE by 20% in non-diabetic patients with obesity and CV disease. Mechanisms, findings, and Australian PBS access.